A
0.737
-0.02 (-3.01%)
| Previous Close | 0.760 |
| Volume | 84,016 |
| Price / Book | 0.250 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,514.78% |
| Diluted EPS (TTM) | -2.34 |
| Quarterly Revenue Growth (YOY) | -57.30% |
| Current Ratio (MRQ) | 5.90 |
| Operating Cash Flow (TTM) | -13.25 M |
| Levered Free Cash Flow (TTM) | -8.46 M |
| Return on Assets (TTM) | -35.70% |
| Return on Equity (TTM) | -59.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Aprea Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
-1.0
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.0 |
| Average | -1.00 |
|
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.90% |
| % Held by Institutions | 40.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vestal Point Capital, Lp | 30 Jun 2026 | 350,000 |
| Sphera Funds Management Ltd. | 30 Jun 2026 | 270,000 |
| Diadema Partners Lp | 30 Jun 2026 | 44,907 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |